Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.

Slides:



Advertisements
Similar presentations
TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac
Advertisements

WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies (19-23 September 2005) TRADE, TRIPS AND ACCESS TO MEDICINES Cecilia Oh Department.
Durban, South Africa January 29 to 31, 2013 Topic 8: Compulsory Licenses Regional Seminar for Certain African Countries on the Implementation and Use of.
The TRIPS Agreement and Public Health
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
BORDER MEASURES AND GOODS IN TRANSIT
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
Ato2461 INTELLECTUAL PROPERTY AND DEVELOPMENT Presentation by Adrian Otten Director, Intellectual Property Division, WTO Secretariat Panel Discussion 7.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
Patent Related Flexibilities in the Pharmaceutical Field
FLEXIBILITIES IN WTO’S TRIPS AGREEMENT FOR ACCESS TO MEDICINES
Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Zambia TRIPS workshop 3 Oct 2013.
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Intellectual Property Rights in the WTO CARSTEN FINK The WTO and the Doha Development Agenda Washington, DC, April 26, 2005.
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Test data protection TRIPS requirements & TRIPS-plus provisions Carlos Correa.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
TRIPS+ provisions in FTAs and the implications for access to medicines Sanya Smith Third World Network 27 August 2005.
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
A presentation by Moses Nkomo Intellectual Property Attorney and Consultant National Workshop on TRIPS and access to medicines in Zimbabwe Holiday Inn,
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
FREE TRADE AGREEMENTS Prathibha Siva Lawyers Collective HIV/AIDS Unit, India East Africa Consultation, September 2010.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.
Overview of presentation
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
WTO and medicines: from Doha to Cancún
Intellectual Property Protection and Access to Medicines
Access to Treatment: People Before Trade
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
Béchir N’Daw, UNAIDS Secretariat
IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
Intellectual Property Rights in Medicines Procurement
Presentation transcript:

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management of HIV, TB and malaria medicines using GFATM grants Bangkok25-31 July 2005 Karin Timmermans - WHO

Patents, TRIPS & access to medicines Recent developments - Global - India Legal issues relevant for procurement Overview of presentation:

Patents are a public policy tool: to promote and reward innovation to disclose the invention, and make it available to society

TRIPS has harmonized standards for patents. For most developing countries, the new standards are higher than their previous standards.

Introduction of TRIPS standards will delay the introduction of generic versions of new drugs TRIPS contains some safeguards, that can be used to mitigate its potential negative effects on access to medicines

The most important safeguards: compulsory licensing parallel importation These safeguards can only be used when incorporated in national laws.

Parallel importation One possible definition: importation without the consent of the patent holder, of a patented product marketed in another country either by the patent holder or his licensee

license granted without permission of the patent holder many countries laws have CL provisions TRIPS allows CL in case of national emergency or extreme urgency, public non- commercial use, to remedy anti-competitive practices etc. TRIPS does NOT limit the grounds for issuing a CL. Compulsory license (CL):

TRIPS does specify conditions to be applied to CL, including: case-by-case decision first: try voluntary license adequate remuneration patent holder non-exclusive, non-assignable predominantly for domestic market Compulsory license (CL):

The Doha Declaration on TRIPS and Public Health Confirms: TRIPS can and should be interpreted and implemented in a manner supportive of WTO members rights to protect public health, particularly access to medicines.

The Doha Declaration... Also says that: –Countries have the right to use compulsory licensing and parallel importation to ensure access to medicines; –Countries are free to determine the grounds for issuing a compulsory license; –LDCs dont have to implement patents and data protection for pharmaceuticals until 2016.

Paragraph 6 of the Doha Declaration … … recognizes that it is not clear how countries with insufficient or no manufacturing capacity can make effective use of compulsory licensing, and instructs the WTOs TRIPS Council to find an expeditious solution to this problem. A solution was agreed on 30 August 2003.

Parallel importation Compulsory license Country with production facilities ++ Country without production facilities + ?? Question:

30 August 2003: Parallel importation Compulsory license Country with production facilities ++ Country without production facilities + v

countries should first notify WTO (except least- developed countries); provide details of drugs to WTO; possibly 2 compulsory licenses (importing and exporting country); special labeling, packaging and/or coloring/shaping; notify WTO of the grant of compulsory license; prevent re-exportation; annual WTO review of the system; some countries have opted out/only for emergency. Key elements of the solution (30 August Decision):

Recent developments at the global level

Decision = waiver, proposes amendment of TRIPS Risk of TRIPS-plus conditions in bilateral/regional trade agreements

TRIPS+ requirements (1): Data exclusivity for pharmaceuticals (5 years, or even more). During the exclusivity period, the Drug Regulatory Authority can not rely on the originators data to register generic versions.

During the exclusivity period: Generic manufacturers will have to submit their own data to prove safety and efficacy Alternatively, they can only enter the market after expiry of the data exclusivity period => They will have to repeat the clinical trials and other tests

Role Drug Admin.: assess safety, efficacy and quality of medicines Drug Admin. is not a patent police TRIPS+ requirements (2): Linkage: the Drug Regulatory Authority should refrain from registering generic versions of drugs under patent.

To remedy anti-competitive behavior For public non-commercial use In case of emergency In case of insufficient supply TRIPS+ requirements (3): Requirements to limit the grounds for issuing a compulsory license:

Thus, there is a need for both health and trade sector to remain vigilant and to work together, to safeguard access to medicines.

Recent developments in India

3 categories of medicines: patented elsewhere before 1995 not affected patented elsewhere between Jan.95 –Dec.04 mailbox patented from 2005 onwards TRIPS rules apply

Mailbox: Applications from (apparently nearly 9,000) Assessment to start January 2005 Patents will be granted for the remaining time ( < 20 years)

The questions: which applications are in the mailbox ??? which patents will be granted ? amendment to the patent law criteria how will companies react ?

Positive point: the production and sale of generic drugs that are already on the market in India can continue; But: only if significant investment, and: royalties need to be paid. Most likely, production, sale and export of existing generic medicines will continue, but prices may rise.

Legal issues relevant for procurement

Medicines are subject to two sets of rules: Intellectual property rights Registration requirements The right to exclude But not the right to market or to use Authorization to put a medicine on the market

Patented?Registered? Originator drug - / ++ Generic version -+ Basic requirements for drug procurement: but…

Possible exemptions for registration: Compassionate use exemptions Public sector procurement / tenders

Public health safeguards that can facilitate access to medicines: Parallel importation Compulsory licensing / 30 August Decision Government use Bolar provision

Government use: A special case of compulsory license – i.e. a compulsory license for the Government itself. Procedures for Government Use tend to be easier; But medicines produced under Government Use license cannot be sold commercially.

So if you want to procure generic medicines, what do you do? Where do you start?

Stepwise approach: 1.Are there patents in the country? If not, you can procure generics (provided they are registered) 2.Are there pharmaceutical patents? If not, you can procure generics (provided …..

Stepwise approach: 3.Which ARVs are under patent in the country? And: how do we find out?

Stepwise approach: 4.Would a generic version of an ARV infringe any patent in the country? If not, generic procurement can proceed. If yes: - buy originator product, or - make use of safeguard mechanisms, if available under national law.

What are countries actually doing?

Cambodia: Patent law in place, but specifies that there will be no patents for pharmaceuticals until Note: - this is allowed for least-developed countries under the WTOs Declaration on the TRIPS Agreement and Public Health (Doha, 2001); - this is something other least-developed countries should also consider.

Thailand: Generic production of ARVs that are not patented in Thailand (incl. ddI powder); Challenging the ddI patent in court

Brazil: Generic production of ARVs that are not patented in Brazil; Negotiating price reductions of ARVs that are patented, using the threat of compulsory licensing

Malaysia & Indonesia: Government Use - Malaysia for importation, - Indonesia (mainly) for local production.

Didanosine Zidovudine Didanosine+Zidovudine Lamivudine Nevirapine Valid for 2 yearsValid for years Royalty to be determinedRoyalty 0.5 % Authorization by Minister of Domestic Trade Presidential Decree MalaysiaIndonesia

Thank you